Contagion, December 2020 (Vol. 05 No. 06)
An expert panel discussion around long-acting injectables' role in both preventing and treating HIV.
Biologics have become a novel treatment in recurrent C. difficile.
Since late 2004, 7 novel antibiotics with activity against ESBL-E, CRE, and/or DTR P aeruginosa have been approved.
Fostemsavir, an HIV-1 attachment inhibitor, is a novel therapeutic option for multidrug-resistant HIV. It represents the first oral agent developed for this indication in over a decade and provides promise for patients with limited remaining treatment options.
Advertisement
Advertisement
Trending on Contagion Live
1
Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Meets Primary Endpoint in Phase 3 Study
2
Zoliflodacin Emerges as a First-in-Class Oral Option Against Drug-Resistant Gonorrhea
3
Caring Holistically: NYU’s Approach to Pediatric Infectious Disease
4
Public Health Wake-Up Call: Will the US Lose Measles Elimination Status?
5
